Detalles de la búsqueda
1.
A phase II study of sequential treatment with anthracycline and taxane followed by eribulin in patients with HER2-negative, locally advanced breast cancer (JBCRG-17).
Breast Cancer Res Treat
; 190(3): 425-434, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34554370
2.
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
N Engl J Med
; 376(22): 2147-2159, 2017 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28564564
3.
A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer.
Breast Cancer Res Treat
; 180(1): 135-146, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-31953696
4.
Predictive factors of an axillary pathological complete response of node-positive breast cancer to neoadjuvant chemotherapy.
Surg Today
; 50(2): 178-184, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-31367884
5.
A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients.
Br J Cancer
; 120(5): 475-480, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30745582
6.
[Toxicity of Palbociclib in Patients Aged 70 Years and Older with Metastatic Breast Cancer].
Gan To Kagaku Ryoho
; 46(7): 1137-1140, 2019 Jul.
Artículo
en Japonés
| MEDLINE | ID: mdl-31296819
7.
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 19(1): 127-138, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29158011
8.
Prediction of postoperative disease-free survival and brain metastasis for HER2-positive breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab using a machine learning algorithm.
Breast Cancer Res Treat
; 172(3): 611-618, 2018 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-30194511
9.
Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial.
Breast Cancer Res Treat
; 161(3): 473-482, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-28005247
10.
Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.
Breast Cancer Res Treat
; 162(3): 501-510, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28181129
11.
Evaluation of the Clinical Utility of the ICG Fluorescence Method Compared with the Radioisotope Method for Sentinel Lymph Node Biopsy in Breast Cancer.
Ann Surg Oncol
; 23(1): 44-50, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26275781
12.
Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy.
BMC Cancer
; 16: 230, 2016 Mar 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-26984766
13.
Phase I study of weekly nab-paclitaxel combined with S-1 in patients with human epidermal growth factor receptor type 2-negative metastatic breast cancer.
Cancer Sci
; 106(6): 734-739, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25786335
14.
Prolonged survival after diagnosis of brain metastasis from breast cancer: contributing factors and treatment implications.
Jpn J Clin Oncol
; 45(8): 713-8, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-25981620
15.
Safety, pharmacokinetics and efficacy findings in an open-label, single-arm study of weekly paclitaxel plus lapatinib as first-line therapy for Japanese women with HER2-positive metastatic breast cancer.
Int J Clin Oncol
; 20(6): 1102-9, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25967286
16.
Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients.
Int J Clin Oncol
; 20(4): 709-22, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-25666483
17.
[Everolimus plus exemestane in postmenopausal patients with estrogen-receptor-positive advanced breast cancer - Japanese subgroup analysis of BOLERO -2].
Gan To Kagaku Ryoho
; 42(1): 67-75, 2015 Jan.
Artículo
en Japonés
| MEDLINE | ID: mdl-25596682
18.
Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression.
Breast Cancer Res Treat
; 145(2): 401-9, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24728578
19.
Evaluating the 21-gene assay Recurrence Score® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer.
Int J Clin Oncol
; 19(4): 607-13, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24101215
20.
A multicenter, phase II study of epirubicin/cyclophosphamide followed by docetaxel and concurrent trastuzumab as primary systemic therapy for HER-2 positive advanced breast cancer (the HER2NAT study).
Int J Clin Oncol
; 18(4): 598-606, 2013 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22833344